EUVIMEDEUVIMED entdecken
Crossref

Chalcone derivative 1m mitigates hepatic fibrosis and inflammation, enhances cholesterol efflux and reduces atherosclerosis

Chih-Feng Lien, Chin-Sheng Lin, Ching-Yuh Chern, Jia-Yu Chen, Rou-Ling Cho, Sy-Jou Chen, Yi-Jhen Huang, Feng-Yen Lin, Chien-Sung Tsai, Yu-Lueng Shih

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Chih-Feng Lien und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Atherosclerosis, Cholesterol, Liver Cirrhosis, Chalcones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Tri-Service General Hospital, National Science and Technology Council, Ministry of National Defense Medical Affairs Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis, which is characterized by lipid dysregulation, remains a major concern in cardiovascular medicine because of its multifactorial nature. Although lipid-lowering therapies, particularly statins, form the cornerstone of atherosclerosis management, issues such as statin intolerance and inadequate responses necessitate the exploration of novel therapeutic modalities. This study aimed to evaluate the hepatoprotective effects of 1m, a chalcone derivative and potential anti-atherosclerotic drug. In atherosclerosis-prone mouse models, the synthesized chalcone derivative 1m effectively reduced hepatic lipid accumulation and improved lipid profiles in high-cholesterol diet (HCD)-fed low-density lipoprotein receptor-knockout (Ldlr-/-) mice. Moreover, 1m promoted the expression of cholesterol regulatory genes, ATP-binding cassette transporters G5 (Abcg5), G8 (Abcg8), and cholesterol 7α-hydroxylase (Cyp7a1), in the liver, resulting in decreased hepatic triglyceride and cholesterol content, alongside increased hepatic bile acid and fecal cholesterol and bile acid contents in HCD-fed Ldlr-/- mice. RNA sequencing identified NR5A2 (liver receptor homolog-1, LRH-1) as a potential mediator of 1m-regulated gene expression, with increased expression observed in the liver of 1m-treated HCD-fed Ldlr-/- mice. In vitro studies using Huh7 hepatocytes revealed that 1m activates LRH-1, promoting its nuclear translocation and upregulating ABCG5, ABCG8, and CYP7A1 expressions, while the effects are attenuated by LRH-1 reverse agonist. Additionally, 1m reduced palmitic acid-induced apoptosis and significantly suppressed TGFβ-induced hepatic fibrosis and inflammation. Importantly, 1m ameliorated liver injury and atherosclerosis in HCD-fed Ldlr-/- mice. Our findings conclude the promising atheroprotective effects of 1m, facilitated by enhanced cholesterol efflux. Additionally, it confers hepatoprotective effects, thereby presenting a novel therapeutic avenue for atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCholesterolLiver CirrhosisChalconesAnimalsMice, KnockoutMiceReceptors, LDLHumansMaleMice, Inbred C57BLLiverCholesterol 7-alpha-HydroxylaseATP Binding Cassette Transporter, Subfamily G, Member 5ATP Binding Cassette Transporter, Subfamily G, Member 8Receptors, Cytoplasmic and NuclearDisease Models, AnimalInflammationLipoproteins

Stichwörter der Autor:innen

AtherosclerosisBile acidChalcone derivativesCholesterol effluxHepatoprotectionLRH-1

Substanzen

CholesterolReceptors, LDLChalconesCholesterol 7-alpha-HydroxylaseATP Binding Cassette Transporter, Subfamily G, Member 5ATP Binding Cassette Transporter, Subfamily G, Member 8Receptors, Cytoplasmic and NuclearABCG5 protein, mouseABCG8 protein, mouseCyp7a1 protein, mouse

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
  • Department of Applied Chemistry, National Chiayi University, Chiayi, Taiwan.
  • Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
  • Department of Internal Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
  • Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
  • Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Taichung Armed Forces General Hospital, Taichung, Taiwan. Electronic address:…

Förderung

  • Tri-Service General Hospital
  • National Science and Technology Council
  • Ministry of National Defense Medical Affairs Bureau

Zitieren

APA

Lien, C. F., Lin, C. S., Chern, C. Y., Chen, J. Y., Cho, R. L., Chen, S. J., Huang, Y. J., Lin, F. Y., Tsai, C. S., & Shih, Y. L. (2025). Chalcone derivative 1m mitigates hepatic fibrosis and inflammation, enhances cholesterol efflux and reduces atherosclerosis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115189

Vancouver

Lien CF, Lin CS, Chern CY, Chen JY, Cho RL, Chen SJ, et al. Chalcone derivative 1m mitigates hepatic fibrosis and inflammation, enhances cholesterol efflux and reduces atherosclerosis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115189

BibTeX
@article{Lien2025,
  author = {Lien, Chih-Feng and Lin, Chin-Sheng and Chern, Ching-Yuh and Chen, Jia-Yu and Cho, Rou-Ling and Chen, Sy-Jou and Huang, Yi-Jhen and Lin, Feng-Yen and Tsai, Chien-Sung and Shih, Yu-Lueng},
  title = {Chalcone derivative 1m mitigates hepatic fibrosis and inflammation, enhances cholesterol efflux and reduces atherosclerosis},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115189}
}
Kostenlos starten →